Checkpoint Inhibitors for Treating Cancer Market

Checkpoint inhibitors for treating cancer is a type of drug that blocks certain proteins made by some types of immune system cells, such as T cells, and some cancer cells. These proteins help keep immune responses in check and can keep T cells from killing cancer cells. When these proteins are blocked, the ?brakes? on the immune system are released and T cells are able to kill cancer cells better. Examples of checkpoint proteins found on T cells or cancer cells include PD-1/PD-L1 and CTLA-4/B7-1/B7-2.

Checkpoint Inhibitors for Treating Cancer Market contains market size and forecasts of Checkpoint Inhibitors for Treating Cancer in global, including the following market information:

Global Checkpoint Inhibitors for Treating Cancer Market Revenue, 2017-2022, 2023-2028, ($ millions)

Global Checkpoint Inhibitors for Treating Cancer Market Sales, 2017-2022, 2023-2028, (g)

Global top five Checkpoint Inhibitors for Treating Cancer companies in 2021 (%)

The global Checkpoint Inhibitors for Treating Cancer market was valued at 12850 million in 2021 and is projected to reach US$ 59580 million by 2028, at a CAGR of 24.5% during the forecast period.

The U.S. Market is Estimated at $ Million in 2021, While China is Forecast to Reach $ Million by 2028.

PD-1 Inhibitors Segment to Reach $ Million by 2028, with a % CAGR in next six years.

The global key manufacturers of Checkpoint Inhibitors for Treating Cancer include Bristol-Myers Squibb(BMS), Merck and Roche, etc. In 2021, the global top five players have a share approximately % in terms of revenue.

MARKET MONITOR GLOBAL, INC (MMG) has surveyed the Checkpoint Inhibitors for Treating Cancer manufacturers, suppliers, distributors and industry experts on this industry, involving the sales, revenue, demand, price change, product type, recent development and plan, industry trends, drivers, challenges, obstacles, and potential risks.

Total Market by Segment:

Global Checkpoint Inhibitors for Treating Cancer Market, by Type, 2017-2022, 2023-2028 ($ Millions) & (g)

Global Checkpoint Inhibitors for Treating Cancer Market Segment Percentages, by Type, 2021 (%)

PD-1 Inhibitors

PD-L1 Inhibitors

CTLA-4 Inhibitors

Global Checkpoint Inhibitors for Treating Cancer Market, by Application, 2017-2022, 2023-2028 ($ Millions) & (g)

Global Checkpoint Inhibitors for Treating Cancer Market Segment Percentages, by Application, 2021 (%)

Melanoma Treatment

Bladder Cancer Treatment

Other

Global Checkpoint Inhibitors for Treating Cancer Market, By Region and Country, 2017-2022, 2023-2028 ($ Millions) & (g)

Global Checkpoint Inhibitors for Treating Cancer Market Segment Percentages, By Region and Country, 2021 (%)

North America

US

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Nordic Countries

Benelux

Rest of Europe

Asia

China

Japan

South Korea

Southeast Asia

India

Rest of Asia

South America

Brazil

Argentina

Rest of South America

Middle East & Africa

Turkey

Israel

Saudi Arabia

UAE

Rest of Middle East & Africa

Competitor Analysis

The report also provides analysis of leading market participants including:

Key companies Checkpoint Inhibitors for Treating Cancer revenues in global market, 2017-2022 (Estimated), ($ millions)

Key companies Checkpoint Inhibitors for Treating Cancer revenues share in global market, 2021 (%)

Key companies Checkpoint Inhibitors for Treating Cancer sales in global market, 2017-2022 (Estimated), (g)

Key companies Checkpoint Inhibitors for Treating Cancer sales share in global market, 2021 (%)

Further, the report presents profiles of competitors in the market, key players include:

Bristol-Myers Squibb(BMS)

Merck

Roche